ValuEngine upgraded shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) from a strong sell rating to a sell rating in a report released on Friday.
Other analysts have also issued reports about the stock. Jefferies Group LLC set a $5.00 target price on shares of Mirati Therapeutics and gave the stock a hold rating in a report on Friday, August 4th. Leerink Swann increased their target price on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the stock a market perform rating in a report on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $8.15.
Shares of Mirati Therapeutics (NASDAQ:MRTX) traded up 135.79% on Friday, hitting $11.20. The stock had a trading volume of 48,767,398 shares. Mirati Therapeutics has a 1-year low of $2.70 and a 1-year high of $12.40. The firm has a 50 day moving average of $5.21 and a 200-day moving average of $4.48. The firm’s market capitalization is $279.65 million.
TRADEMARK VIOLATION NOTICE: “Mirati Therapeutics, Inc. (MRTX) Upgraded to “Sell” by ValuEngine” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://transcriptdaily.com/2017/09/16/mirati-therapeutics-inc-mrtx-upgraded-to-sell-by-valuengine.html.
A number of institutional investors and hedge funds have recently modified their holdings of MRTX. KCG Holdings Inc. purchased a new stake in Mirati Therapeutics in the first quarter worth about $106,000. Susquehanna International Group LLP lifted its holdings in Mirati Therapeutics by 46.5% in the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after buying an additional 16,030 shares during the period. PDT Partners LLC purchased a new stake in Mirati Therapeutics in the second quarter worth about $200,000. Trexquant Investment LP lifted its holdings in Mirati Therapeutics by 62.2% in the first quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16,447 shares during the period. Finally, LMR Partners LLP purchased a new stake in Mirati Therapeutics in the second quarter worth about $236,000. Institutional investors and hedge funds own 60.17% of the company’s stock.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.